Literature DB >> 17562761

Borrelia garinii induces CXCL13 production in human monocytes through Toll-like receptor 2.

Tobias A Rupprecht1, Carsten J Kirschning, Bernadette Popp, Stefan Kastenbauer, Volker Fingerle, Hans-Walter Pfister, Uwe Koedel.   

Abstract

Recent studies have suggested an important role for the B-cell-attracting chemokine CXCL13 in the B-cell-dominated cerebrospinal fluid (CSF) infiltrate in patients with neuroborreliosis (NB). High levels of CXCL13 were present in the CSF of NB patients. It has not been clear, however, whether high CSF CXCL13 titers are specific for NB or are a characteristic of other spirochetal diseases as well. Furthermore, the mechanisms leading to the observed CXCL13 expression have not been identified yet. Here we describe similarly elevated CSF CXCL13 levels in patients with neurosyphilis, while pneumococcal meningitis patient CSF do not have high CXCL13 levels. In parallel, challenge of human monocytes in vitro with two of the spirochetal causative organisms, Borrelia garinii (the Borrelia species most frequently found in NB patients) and Treponema pallidum, but not challenge with pneumococci, induced CXCL13 release. This finding implies that a common spirochetal motif is a CXCL13 inducer. Accordingly, we found that the lipid moiety N-palmitoyl-S-(bis[palmitoyloxy]propyl)cystein (Pam(3)C) (three palmitoyl residues bound to N-terminal cysteine) of the spirochetal lipoproteins is critical for the CXCL13 induction in monocytes. As the Pam(3)C motif is known to signal via Toll-like receptor 2 (TLR2) and an anti-TLR2 monoclonal antibody blocked CXCL13 production of human monocytes incubated with B. garinii, this suggests that TLR2 is a major mediator of Borrelia-induced secretion of CXCL13 from human monocytes.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17562761      PMCID: PMC1951179          DOI: 10.1128/IAI.01642-06

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  25 in total

1.  Toll-like receptor 2 is required for innate, but not acquired, host defense to Borrelia burgdorferi.

Authors:  R Mark Wooten; Ying Ma; R Alyson Yoder; Jeanette P Brown; John H Weis; James F Zachary; Carsten J Kirschning; Janis J Weis
Journal:  J Immunol       Date:  2002-01-01       Impact factor: 5.422

2.  The chemokine CXCL13 (BLC): a putative diagnostic marker for neuroborreliosis.

Authors:  T A Rupprecht; H W Pfister; B Angele; S Kastenbauer; B Wilske; U Koedel
Journal:  Neurology       Date:  2005-08-09       Impact factor: 9.910

3.  Short-lived plasma blasts are the main B cell effector subset during the course of multiple sclerosis.

Authors:  Sabine Cepok; Berit Rosche; Verena Grummel; Friederike Vogel; Dun Zhou; Joachim Sayn; Norbert Sommer; Hans-Peter Hartung; Bernhard Hemmer
Journal:  Brain       Date:  2005-03-30       Impact factor: 13.501

Review 4.  Immune evasion of the Lyme disease spirochetes.

Authors:  Sarah Bubeck-Martinez
Journal:  Front Biosci       Date:  2005-01-01

5.  Activation-dependent modulation of B lymphocyte migration to chemokines.

Authors:  M Brandes; D F Legler; B Spoerri; P Schaerli; B Moser
Journal:  Int Immunol       Date:  2000-09       Impact factor: 4.823

6.  Lipoteichoic acid (LTA) of Streptococcus pneumoniae and Staphylococcus aureus activates immune cells via Toll-like receptor (TLR)-2, lipopolysaccharide-binding protein (LBP), and CD14, whereas TLR-4 and MD-2 are not involved.

Authors:  Nicolas W J Schröder; Siegfried Morath; Christian Alexander; Lutz Hamann; Thomas Hartung; Ulrich Zähringer; Ulf B Göbel; Joerg R Weber; Ralf R Schumann
Journal:  J Biol Chem       Date:  2003-02-19       Impact factor: 5.157

7.  Microbial lipopeptides stimulate dendritic cell maturation via Toll-like receptor 2.

Authors:  C J Hertz; S M Kiertscher; P J Godowski; D A Bouis; M V Norgard; M D Roth; R L Modlin
Journal:  J Immunol       Date:  2001-02-15       Impact factor: 5.422

8.  Human but not murine toll-like receptor 2 discriminates between tri-palmitoylated and tri-lauroylated peptides.

Authors:  Alina Grabiec; Guangxun Meng; Sylvia Fichte; Wolfgang Bessler; Hermann Wagner; Carsten J Kirschning
Journal:  J Biol Chem       Date:  2004-09-01       Impact factor: 5.157

9.  Hyporesponsiveness to vaccination with Borrelia burgdorferi OspA in humans and in TLR1- and TLR2-deficient mice.

Authors:  Lena Alexopoulou; Venetta Thomas; Markus Schnare; Yves Lobet; Juan Anguita; Robert T Schoen; Ruslan Medzhitov; Erol Fikrig; Richard A Flavell
Journal:  Nat Med       Date:  2002-07-01       Impact factor: 53.440

10.  Borrelia burgdorferi lipoprotein-mediated TLR2 stimulation causes the down-regulation of TLR5 in human monocytes.

Authors:  Erik S Cabral; Harald Gelderblom; Ronald L Hornung; Peter J Munson; Roland Martin; Adriana R Marques
Journal:  J Infect Dis       Date:  2006-02-08       Impact factor: 5.226

View more
  35 in total

1.  [CXCL13: a biomarker for acute Lyme neuroborreliosis: investigation of the predictive value in the clinical routine].

Authors:  T A Rupprecht; C Lechner; H Tumani; V Fingerle
Journal:  Nervenarzt       Date:  2014-04       Impact factor: 1.214

2.  HIV-1 single-stranded RNA induces CXCL13 secretion in human monocytes via TLR7 activation and plasmacytoid dendritic cell-derived type I IFN.

Authors:  Kristen W Cohen; Anne-Sophie Dugast; Galit Alter; M Juliana McElrath; Leonidas Stamatatos
Journal:  J Immunol       Date:  2015-02-09       Impact factor: 5.422

Review 3.  Lyme Neuroborreliosis: Clinical Outcomes, Controversy, Pathogenesis, and Polymicrobial Infections.

Authors:  Juan Carlos Garcia-Monco; Jorge L Benach
Journal:  Ann Neurol       Date:  2019-01       Impact factor: 10.422

4.  MyD88- and TRIF-independent induction of type I interferon drives naive B cell accumulation but not loss of lymph node architecture in Lyme disease.

Authors:  Christine J Hastey; Jennine Ochoa; Kimberley J Olsen; Stephen W Barthold; Nicole Baumgarth
Journal:  Infect Immun       Date:  2014-01-22       Impact factor: 3.441

5.  Toward a better understanding of European lyme neuroborreliosis.

Authors:  Gary P Wormser; John J Halperin
Journal:  Clin Infect Dis       Date:  2013-05-10       Impact factor: 9.079

6.  Has CXCL13 an added value in diagnosis of neurosyphilis?

Authors:  Khutso M Mothapo; Marcel M Verbeek; Lieven B van der Velden; C Wim Ang; Peter P Koopmans; Andre van der Ven; Foekje Stelma
Journal:  J Clin Microbiol       Date:  2015-03-18       Impact factor: 5.948

7.  CXCR5 overexpression in HL-60 cells enhances chemotaxis toward CXCL13 without anticipated interaction partners or enhanced MAPK signaling.

Authors:  Robert J MacDonald; Andrew Yen
Journal:  In Vitro Cell Dev Biol Anim       Date:  2018-10-01       Impact factor: 2.416

8.  Cerebrospinal fluid proteome of patients with acute Lyme disease.

Authors:  Thomas E Angel; Jon M Jacobs; Robert P Smith; Mark S Pasternack; Susan Elias; Marina A Gritsenko; Anil Shukla; Edward C Gilmore; Carol McCarthy; David G Camp; Richard D Smith; H Shaw Warren
Journal:  J Proteome Res       Date:  2012-08-31       Impact factor: 4.466

9.  CSF B--lymphocyte chemoattractant (CXCL13) in the early diagnosis of acute Lyme neuroborreliosis.

Authors:  Unn Ljøstad; Ase Mygland
Journal:  J Neurol       Date:  2008-03-17       Impact factor: 4.849

10.  The chemokine CXCL13 is a key regulator of B cell recruitment to the cerebrospinal fluid in acute Lyme neuroborreliosis.

Authors:  Tobias A Rupprecht; Andreas Plate; Michaela Adam; Manfed Wick; Stefan Kastenbauer; Caroline Schmidt; Matthias Klein; Hans-Walter Pfister; Uwe Koedel
Journal:  J Neuroinflammation       Date:  2009-12-30       Impact factor: 8.322

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.